EODData

MEMBERSHIP REGISTER LOG IN

FRA, I7G0: IPSEN SA SP.ADR 1/4/ EO 1

27 Mar 2026
LAST:

38.00

CHANGE:
 0.40		OPEN:
38.00		HIGH:
38.00		ASK:
0.00		VOLUME:
0
CHG(%):
1.06		PREV:
37.60		LOW:
38.00		BID:
0.00		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
27 Mar 2638.0038.0038.0038.000
26 Mar 2637.6037.6037.6037.60572
25 Mar 2637.2037.2037.2037.20572
24 Mar 2637.0037.0037.0037.00572
23 Mar 2636.6036.6036.6036.60572
20 Mar 2638.0038.0038.0038.00572
19 Mar 2637.8037.8037.8037.800
18 Mar 2639.4039.4039.4039.400
17 Mar 2638.2038.2038.2038.200
16 Mar 2638.0038.0038.0038.000

PROFILE

Name:IPSEN SA SP.ADR 1/4/ EO 1
About:Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Sector:Healthcare
Address:65, quai Georges Gorse, Boulogne-Billancourt, France, 92100
Website:https://www.ipsen.com
ISIN:US4626292050
LEI:549300M6SGDPB4Z94P11

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:22.54 
Forward P/E:10.63 
Price to Sales:2.66 
Price to Book:0.59 
Profit Margin:0.12 
Operating Margin:0.26 
Return on Assets:0.10 
Return on Equity:0.11 
DivYield:0.05 
Div/Share:1.40 
Revenue:3.76B 
EBITDA:1.377B 
Shares:330.76M 
Market Cap:12.569B 

TECHNICAL INDICATORS

MA5:37.281.9%
MA10:37.780.6%
MA20:38.681.8%
MA50:36.833.2%
MA100:33.8212.4%
MA200:30.7223.7%
STO9:50.00
STO14:50.00
RSI14:44.44
WPR14:-50.00
MTM14:-0.80
ROC14:-0.02 
ATR:0.51 
Week High:38.000.0%
Week Low:36.603.8%
Month High:41.208.4%
Month Low:36.6023.7%
Year High:41.208.4%
Year Low:22.7866.8%
Volatility:20.83 

RECENT DIVIDENDS

Date Amount
09 Jun 2025$0.34
31 May 2024$0.28
02 Jun 2023$0.27
31 May 2022$0.27